Glucos Viaflo Baxter

Glucos Viaflo Baxter is an injectable solution containing glucose as the sole active ingredient, supplied in a sterile aqueous formulation for intravenous administration. The product is marketed in the European Union and is prescribed as a parenteral source of carbohydrate when oral intake is insufficient or when rapid correction of low blood glucose is required. It is provided without a specified concentration on the label.

Glucos Viaflo Baxter is used in clinical settings to supply carbohydrate energy and maintain fluid balance when oral nutrition is not feasible.

- Treatment of hypoglycemia in patients unable to take oral glucose. - Component of total parenteral nutrition regimens for patients requiring intravenous carbohydrate support. - Fluid replacement in conjunction with electrolytes for dehydration or surgical patients. - Support during perioperative fasting to prevent energy deficit. - Adjunct in neonatal intensive care for infants with low blood glucose. - Used for electrolyte‑balanced rehydration in patients with gastrointestinal losses.

Glucos Viaflo Baxter may be associated with infusion‑related reactions and metabolic changes, which are typically categorized by frequency and severity.

Common: - Transient hyperglycemia or elevated blood glucose levels, usually resolving after infusion cessation. - Mild infusion site irritation or erythema, typically transient. - Nausea or mild abdominal discomfort. - Headache or dizziness during rapid infusion. - Temporary increase in serum osmolality. - Mild metabolic acidosis in patients with renal impairment.

Serious: - Severe hyperglycemia leading to osmotic diuresis, may require insulin therapy. - Hypotension from rapid fluid administration. - Electrolyte imbalance, particularly hyponatremia. - Allergic reaction such as urticaria or anaphylaxis. - Volume overload leading to pulmonary edema in patients with cardiac dysfunction.

When prescribing Glucos Viaflo Baxter, clinicians should assess patient-specific factors and monitor for potential complications related to glucose infusion and fluid volume.

- Verify baseline blood glucose and adjust infusion rate to avoid hyperglycemia. - Assess renal and hepatic function before administration, as clearance may be altered. - Evaluate cardiac status to prevent volume overload in patients with heart failure. - Use caution in pregnant or lactating women; limited safety data are available. - Monitor electrolytes, especially sodium and potassium, during prolonged therapy. - Ensure aseptic technique to reduce risk of catheter‑related infection.

Glucos Viaflo Baxter can interact with other agents that affect blood glucose, fluid balance, or electrolyte status, requiring careful coordination with concurrent therapies.

Avoid: - Co‑administration with high‑dose insulin without glucose monitoring, due to risk of severe hypoglycemia. - Rapid infusion together with other hypertonic solutions, which may cause abrupt osmotic shifts. - Concurrent administration with other glucose‑containing solutions, which may lead to excessive caloric load.

Use with caution: - Concurrent use of diuretics that may exacerbate electrolyte disturbances. - Patients receiving total parenteral nutrition containing other carbohydrate sources; monitor total glucose load. - Anticoagulants, as large fluid volumes can dilute plasma concentrations. - Beta‑blockers, because they may mask symptoms of hypoglycemia.